CORRESPONDENCE
Several studies have determined that t(12;21) is involved exclusively in B-lineage ALL, mostly in children, and is associated with an excellent prognosis. [6] [7] [8] [9] Recently, however, Borkhardt et al 10 reported that even though patients with the positive chimeric transcript are good responders and achieve CCR, they may develop late relapses. Therefore it is of the utmost importance to identify, at diagnosis, patients in the standard risk group with the tendency to relapse.
In the present study, we analyzed 98 B-lineage childhood ALL patients for the TEL-AML1 fusion transcript at diagnosis and correlated the findings with duration of remission according to treatment protocol.
Twenty-four of the 98 patients (24%) studied at diagnosis were positive for the TEL-AML1 transcript. The clinical features of the children who were positive or negative for the TEL-AML1 fusion transcript are summarized in Table 1 . There were no significant differences between the groups in age, DNA index (DI), leukocyte count, phenotype (CD10 + vs CD10 − ) or response to therapy. Seventy-five percent of the positive patients peaked at age 2-6 although only 38% of the negative patients were in this age group. A recent study showed that the age distribution of TEL-AML1-positive patients peaked at 2-4 years.
11 Eighty-four percent had a leukocyte count of less than 50 000/l ( Table 1) . The majority had a diploid DNA content, generally associated with a less favorable prognosis. Good response to therapy, defined as the achievement of remission by day 23 or before, was noted in 87% of the TEL-AML1-positive children compared to 65% of the TEL-AML1-negative children (P = 0.06).
Relapse occurred in 12.5% (3/24) of the positive group and 22% (16/74) of the negative group. The median duration of remission was 56 months and 19 months in the positive and negative groups, respectively. Table 1 Comparison between patients positive (n = 24) and negative (n = 74) for TEL-AML1
Positive
Negative P value n (%) n (%) The event-free survival (EFS) rates at 57 months were 82% in the TEL-AML1 positive group and 69% in the negative group (P = 0.09). It was noteworthy that in the positive TEL-AML1 group, two of the relapses occurred at 56 months or later. In the case of the third child, treatment was interrupted for long periods due to CNS toxicity and he relapsed at 29 months. In the negative group most relapses occurred before 24 months (Figure 1a) . A similar pattern, reaching a borderline significance (P = 0.06), was observed in the overall survival curves (Figure 1b) . The disease-free survival was identical to the EFS (P = 0.04).
The two treatment protocols used differed conceptually by longer duration and less intensivity. INS 84 included induction with five drugs: prednisone (P), vincristine (V), asparaginase (As), anthracycline (Ant) and cyclophosphomide (CTX). Intensification of 12 monthly repeated pulses with a combination of five drugs: V, P, Ant, CTX and Ara-C and maintenance with oral 6-mercaptopurine (6-MP) and methotrexate (MTX) up to 4 years from diagnosis. INS 89 protocol based on BFM 86 was much more intensive upfront with seven drugs during the first 9 weeks of induction/reinduction including: P, V, As, Ant, CTX, Ara-C and 6-MP. Consolidation with highdose MTX and VP-16 (the latter was an Israeli modification) and then 7 weeks of delayed intensification similar to the induction/reinduction; all together, 7 months of intensive systemic treatment. Maintenance with 6-MP, MTX continued for a total of 2 years. CNS preventive therapy in the INS 84 was randomized between cranial irradiation and extended triple intra-thecal (TIT) and in the INS 89 all children received TIT only. Life table analysis of EFS in the TEL-AML1-positive patients by treatment protocol yielded better results at 57 months for the more intensive INS 89 (94%) than for the INS 84 (66%) (P = 0.25) (Figure 2a, b) .
No additional positive TEL-AML1 results were detected in the 27 patients in relapse. This is in concordance with two new studies on relapsed ALL with low frequency of TEL-AML1.
12, 13 Seeger et al 14 noted an identical incidence of TEL-AML1 positivity to that in the majority of samples at diagnosis. The positive and negative TEL-AML1 groups differed significantly with respect to duration of remission and age at diagnosis.
The only sample positive for the TEL-AML1 transcript in relapse belonged to a patient with a positive funding also at diagnosis. No relapse samples from the two additional posi-tive patients at diagnosis were available. All other relapse samples were negative. Thus, we do not favor the speculative hypothesis that the high incidence of TEL-AML1 transcript in relapse might be a consequence of a new genetic alteration.
14 Even in our small relapse sample we were able to identify a striking difference in the duration of remission similar to the results of Seeger et al. 14 In the three TEL-AML1-positive patients who relapsed, all (100%) had a remission longer than 24 months, with a median of 56 months, whereas in the negative TEL-AML1 group who relapsed, only 50% (13/26) had a remission duration of more than 24 months, with a median of 21 months.
We believe that the TEL-AML1 transcript is an additional marker for good prognosis at diagnosis. It can be of the utmost importance in defining minimal residual disease during therapy, and if monitored regularly, may be used to identify patients at risk of late relapse, in whom augmented upfront intensive therapy may improve the outcome. This was illustrated in the more recent two treatment protocol, showing that the upfront intensive therapy dramatically improved the outcome in the TEL-AML1-positive children (94% vs 66%) at a median follow-up of 57 months (P = 0.25). A similar observation was recently reported from Japan by Takahashi et al. 15 A longer follow-up is required before we can definitively conclude that the current protocal is optimal for TEL-AML1-positive children. An alternative may be to apply the augmented chemotherapy during maintenance therapy.
Our data support the importance of molecular monitoring in identifying the favorable subset of children with positive TEL-AML1 fusion transcript at diagnosis, in whom upfront appropriate intensive therapy is associated with a long-term event-free survival.
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